AAFP Antibiotics for Acute Uncomplicated Diverticulitis Does antibiotic therapy for acute uncomplicated diverticulitis reduce complications and the need for emergency surgery? September 15, 2023
AAFP Antibiotics for Acute Uncomplicated Diverticulitis Does antibiotic therapy for acute uncomplicated diverticulitis reduce complications and the need for emergency surgery? September 15, 2023
Early Mayo Clinic study finds hope for stem cell therapy for perianal fistulas in Crohn’s disease patients
ROCHESTER, Minn. — Dissolvable plug enables stem cell therapy with few side effects for single-tube patients perianal fistula, mayo clinic discovered by researchers. Perianal fistulas are painful tunnels between the intestines and skin that often do not go away with standard medical or surgical treatments.person who has crohn’s disease or other inflammatory bowel disease Who […]
Brain-gut connection explains why integrative therapy can help alleviate digestive disorders
Throughout the 20th century, medicine has become very good at breaking down the different systems of the body to better understand them. However, today we are becoming increasingly aware that the various systems of the body are interconnected and cannot be fully understood in isolation. The brain-gut connection is one very important example of this […]
Fruquintinib combination therapy improves quality-adjusted survival in metastatic colorectal cancer
3D illustration of the colon – Stock.adobe.com The combination of fruquintinib (Fruzakura) and optimal supportive care led to Results from an in-phase post-hoc analysis show that quality-adjusted time to absence of symptoms of disease or toxicity increased when compared with placebo and optimal supportive care in previously treated patients with metastatic colorectal cancer (CRC). The […]
From immunomodulatory drugs to microRNA therapy
Inflammatory bowel disease (IBD) refers to a group of chronic intestinal inflammatory conditions, primarily ulcerative colitis (UC) and Crohn’s disease (CD). These autoimmune mucosal damage conditions cause pain, bloating, indigestion, and acute abdominal emergencies, significantly reducing quality of life in the long term. Newer treatments have emerged based on a better understanding of the pathophysiology […]
First-in-class targeted therapy has potential for colon cancer
Germany’s Merck KGaA (MRK:DE) announced a licensing agreement with New York-based small molecule developer Inspirna. The agreement is for ompenacrid, a first-in-class SLC6A8 blocker, and will also include other similar follow-on compounds. Omphenacrid is currently being evaluated in a Phase II trial for second-line treatment of certain people with advanced or metastatic colorectal cancer (mCRC). […]
Some patients with rectal cancer can safely forego neoadjuvant radiation therapy
Preoperative radiation therapy can be safely omitted for many patients with non-locally advanced rectal cancer, according to a study published today. JAMA Oncology. Researchers found that a 50% absolute reduction in the use of radiation therapy at the national level did not worsen outcomes for patients with locally advanced rectal cancer. To examine the impact […]
Cognitive behavioral therapy for irritable bowel syndrome
Cognitive behavioral therapy (CBT) may be a helpful option to treat symptoms of irritable bowel syndrome (IBS) as researchers identify a link between the digestive system and the brain. Irritable bowel syndrome (IBS) refers to a group of gastrointestinal (GI) symptoms that regularly appear together. It is classified as a functional gastrointestinal disease, meaning the […]
BMS Demonstrates Rationale for Opdivo and Yervoy Combination Therapy in First-Line Colorectal Cancer
Photo: California BMS Building Exterior/iStock, hapa bapa Bristol-Myers Squibb on Thursday announced data from the Phase 3 CheckMate-8HW study demonstrating first-line potential for Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy in metastatic colorectal cancer. . BMS did not provide specific data in Thursday’s announcement, but the company said the combination therapy showed “statistically significant results” […]
New targeted therapy for colorectal cancer approved in the US
Japanese pharmaceutical giant Takeda Pharmaceutical (TYO: 4502) has received US approval for Fluzakura (fruquintinib), an oral targeted therapy for colorectal cancer. The U.S. Food and Drug Administration’s decision targets the treatment of metastatic colorectal cancer (mCRC) in patients who have already tried other options, such as chemotherapy or anti-VEGF therapy. Fluzacra, an oral and chemotherapy-free […]